References
1. Yin, Zeyu et al. “Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular disease.” Cell death discovery vol. 8,1 119. 16 Mar. 2022, doi:10.1038/s41420-022-00927-4
2. Tam, Constantine S et al. “Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.” Blood vol. 134,11 (2019): 851-859. doi:10.1182/blood.2019001160
3. Hillmen, Peter et al. “Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.” Journal of clinical oncology: official journal of the American Society of Clinical Oncology, JCO2200510. 17 Nov. 2022, doi:10.1200/JCO.22.00510
4. Chamilos, Georgios et al. “Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.” Clinical infectious diseases: an official publication of the Infectious Diseases Society of America vol. 66,1 (2018): 140-148. doi:10.1093/cid/cix687
5. Estupiñán, H Yesid et al. “Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects.” Frontiers in cell and developmental biology vol. 9 630942. 11 Mar. 2021, doi:10.3389/fcell.2021.630942
6. Rogers, Kerry A et al. “Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies.” Leukemia vol. 33,10 (2019): 2527-2530. doi:10.1038/s41375-019-0481
7. Maffei, Rossana et al. “Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.” Blood reviews vol. 40 (2020): 100635. doi:10.1016/j.blre.2019.100635